1416161-72-2

Upstream product

• 190906-91-3 3,4-dihydro-2-methyl-4-oxo-1(2H)-pyridinecarboxylic acid phenylmethyl ester 
• 620-08-6 4-methoxypyridine 
• 849928-34-3 benzyl 2-methyl-4-oxopiperidine-1-carboxylate 
• 921599-74-8 benzyl (2S)-2-methyl-4-oxopiperidine-1-carboxylate 
• 1227685-18-8 benzyl (2S,4S)-4-hydroxy-2-methyl-4-(trichloromethyl)-piperidine-1-carboxylate 
• 1227685-41-7 (2S,4R)-1-benzyl 4-methyl 4-(3-fluorophenylamino)-2-methylpiperidine-1,4-dicarboxylate 
• 1227685-11-1 benzyl (2S,4R)-4-cyano-4-[(3-ethoxy-3-oxopropanoyl)(3-fluorophenyl)amino]-2-methylpiperidine-1-carboxylate 
• 1227685-13-3 benzyl (5R,7S)-1-(3-fluorophenyl)-4-hydroxy-7-methyl-2-oxo-1,8-diazaspiro[4.5]decane-8-carboxylate 
• 1227685-14-4 (5R,7S)-benzyl 1-(3-fluorophenyl)-7-methyl-2-oxo-1,8-diazaspiro[4.5]dec-3-ene-8-carboxylate 
• 6358-77-6 5-bromo-2-methoxyaniline 
• 1416161-82-4 1-benzyl 4-methyl (2S,4R)-4-[(3-ethoxy-3-oxopropanoyl)(3-fluorophenyl)amino]-2-methylpiperidine-1,4-dicarboxylate 
• 1416161-83-5 8-benzyl 3-ethyl (5R,7S)-1-(3-fluorophenyl)-7-methyl-2,4-dioxo-1,8-diazaspiro[4.5]decane-3,8-dicarboxylate 
• 1416161-80-2 4-hydroxy-3-(5-methyl-1H-pyrazol-1-yl)benzaldehyde 
• 1395896-56-6 1-(5-bromo-2-methoxyphenyl)-5-methyl-1H-pyrazole 

Downstream Products

• 1416161-71-1 C₂₆H₂₇FN₄O₂*ClH 

Relevant academic research and scientific papers

Process development and scale-up of a β-secretase inhibitor via a stereospecific jocic reaction

A scalable process for the synthesis of a spiropiperidine β-secretase inhibitor is described. Key stereochemical transformations utilized are a diastereoselective trichloromethyl addition followed by an unprecedented stereospecific Jocic reaction with an aniline nucleophile. Simplified processing was developed for a Dieckmann cyclization/decarboxylation sequence to give a process suitable for the production of kilogram quantities of API.

LACTAMS AS BETA SECRETASE INHIBITORS

Compound and pharmaceutically acceptable salts of the compound are disclosed, wherein the compound has the structure (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermedia